110 related articles for article (PubMed ID: 20495334)
1. [A case report of a patient treatable by home palliative care, administered zoledronic acid used for bladder cancer with hypercalcemia].
Murakami N; Tanabe K; Murasugi K; Kadoya S; Matsumoto Y; Yoshii I; Fujikawa Y; Ohura F
Gan To Kagaku Ryoho; 2010 May; 37(5):939-42. PubMed ID: 20495334
[TBL] [Abstract][Full Text] [Related]
2. Modern management of malignant hypercalcemia.
Legrand SB
Am J Hosp Palliat Care; 2011 Nov; 28(7):515-7. PubMed ID: 21724679
[TBL] [Abstract][Full Text] [Related]
3. Small cell carcinoma of the urinary bladder with hypercalcemia.
Sendur MA; Aksoy S; Arık Z; Yaman S; Ozdemir NY; Uncu D; Zengin N
Med Oncol; 2012 Jun; 29(2):827-8. PubMed ID: 21499925
[No Abstract] [Full Text] [Related]
4. Chronic Myeloid Leukemia Associated Hypercalcemia: A Case Report and Literature Review.
Toro-Tobón D; Agosto S; Ahmadi S; Koops M; Bruder JM
Am J Case Rep; 2017 Feb; 18():203-207. PubMed ID: 28239141
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
Lin PH; Chiu CF; Lu YS
Ann Oncol; 2011 May; 22(5):1244-1246. PubMed ID: 21460375
[No Abstract] [Full Text] [Related]
6. [Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia].
Shen G; Song ST; Jiang ZF; Bian SG; Xie GR; Wang YJ; Wang JJ
Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):632-4. PubMed ID: 16438878
[TBL] [Abstract][Full Text] [Related]
7. [Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
Tomoo T; Suzuki M
Nihon Yakurigaku Zasshi; 2005 Nov; 126(5):353-7. PubMed ID: 16394581
[No Abstract] [Full Text] [Related]
8. Mismanagement of malignant hypercalcaemia.
Lightowlers S; Patterson D
Clin Med (Lond); 2013 Feb; 13(1):118. PubMed ID: 23472518
[No Abstract] [Full Text] [Related]
9. Hypercalcemia of malignancy remains a clinically relevant problem.
Van Poznak C
Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
[No Abstract] [Full Text] [Related]
10. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Locker GJ; Sevelda U; Zielinski CC; Steger GG
Support Care Cancer; 2004 Sep; 12(9):678-81. PubMed ID: 15160319
[TBL] [Abstract][Full Text] [Related]
11. Hypercalcemia and osteolytic lesions as presenting symptoms of acute lymphoblastic leukemia in childhood. The use of zoledronic acid and review of the literature.
Kolyva S; Efthymiadou A; Gkentzi D; Karana-Ginopoulou A; Varvarigou A
J Pediatr Endocrinol Metab; 2014 Mar; 27(3-4):349-54. PubMed ID: 23934636
[TBL] [Abstract][Full Text] [Related]
12. Severe hypercalcemia as a form of acute lymphoblastic leukemia presentation in children.
Martins AL; Moniz M; Nunes PS; Abadesso C; Loureiro HC; Duarte X; Almeida HI
Rev Bras Ter Intensiva; 2015; 27(4):402-5. PubMed ID: 26761480
[TBL] [Abstract][Full Text] [Related]
13. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
14. Hypercalcemia and gallium nitrate.
Gucalp R
J Support Oncol; 2004; 2(6):518-20. PubMed ID: 16329218
[No Abstract] [Full Text] [Related]
15. Zoledronic acid treatment at home: safety data from an observational prospective trial.
Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
17. Treatment of bisphosphonate-resistant hypercalcemia of malignancy with calcitonin.
Dawson C; Todd AM; Walton A
J Palliat Med; 2014 Oct; 17(10):1084. PubMed ID: 25265187
[No Abstract] [Full Text] [Related]
18. Glucocorticoid sparing effect of zoledronic acid in sarcoid hypercalcemia.
Kuchay MS; Mishra SK; Bansal B; Farooqui KJ; Sekhar L; Mithal A
Arch Osteoporos; 2017 Dec; 12(1):68. PubMed ID: 28726113
[TBL] [Abstract][Full Text] [Related]
19. A dose-finding study of zoledronate in hypercalcemic cancer patients.
Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
[TBL] [Abstract][Full Text] [Related]
20. Rare association between penile squamous cell carcinoma and parathyroid related peptide (PTH-rP) secretion.
Trejo-Rosales R; Nevarez-Barragan MJ; Rosas-Jurado MG; Perez-Diaz I; Bezaury AP
Arq Bras Endocrinol Metabol; 2014 Aug; 58(6):646-9. PubMed ID: 25211448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
